Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.6.0.2
Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Net sales $ 131,807 $ 120,907 $ 262,388 $ 233,288
Operating income 16,146 36,025 41,587 67,054
Costs recognized on sale of acquired inventory (3,848) (1,245) (8,069) (2,357)
Amortization of acquisition related intangible assets     (21,815)  
Acquisition related expenses (10,732) (670) (15,101) (970)
Stock based compensation (4,055) (2,321) (7,245) (4,359)
Corporate general, selling, and administrative (55,655) (34,585) (101,918) (67,625)
Acquisition Related [Member]        
Amortization of acquisition related intangible assets (11,627) (7,361) (21,815) (14,772)
Operating Segments [Member]        
Operating income 47,118 48,811 96,110 91,668
Intersegment Eliminations [Member]        
Net sales (24) (7) (36) (28)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative (710) (1,189) (2,293) (2,156)
Biotechnology [Member] | Operating Segments [Member]        
Net sales 85,953 75,854 172,740 151,597
Operating income 39,474 39,986 81,954 79,302
Diagnostics [Member] | Operating Segments [Member]        
Net sales 24,330 25,723 48,563 46,085
Operating income 5,801 7,297 12,104 12,010
Protein Platforms [Member] | Operating Segments [Member]        
Net sales 21,548 19,337 41,121 35,634
Operating income $ 1,843 $ 1,528 $ 2,052 $ 356